+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 75Years
All Genders
ID07627711

Phase 12 Study of Dual-targeting CAR-NK Cell Therapy for Advanced Pancreatic Ductal Adenocarcinoma Biomarker-Guided Dose-Escalation and Expansion Evaluating MSLNMUC1 and CLDN18.2MUC1 Targets

Led by Beijing Biotech · Updated on 2026-06-04

42

Participants Needed

1

Research Sites

48 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating investigational dual-targeting chimeric antigen receptor natural killer CAR-NK cell products for patients with advanced pancreatic ductal adenocarcinoma PDAC. The study focuses on safety, tolerability, and preliminary anti-tumor activity. Participants are assigned to one of two groups based on tumor antigen expression Arm A targets Mesothelin MSLN andor MUC1, while Arm B targets Claudin 18.2 CLDN18.2 andor MUC1. The trial uses a dose-escalation and dose-expansion approach to identify a recommended dose for further study and to estimate response rates in each group. The treatments involve two off-the-shelf CAR-NK cell products EB-DNK101 targeting MSLN and MUC1, and EB-DNK102 targeting CLDN18.2 and MUC1. Participants first receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide, followed by an intravenous infusion of the assigned CAR-NK product. Repeat infusions of up to three total may be given if there is no prohibitive toxicity and disease remains stable. Tumor tissue is tested centrally to determine antigen expression and assign participants to the appropriate group. Participants will be closely monitored for side effects such as cytokine release syndrome, neurotoxicity, and infusion reactions, especially during the first 28 days after infusion. Tumor response will be assessed every 8 weeks using imaging scans. Additional evaluations include measuring CAR-NK cell persistence, cytokine levels, and antigen density associations. The study will also conduct an internal scientific review to prioritize the lead CAR-NK construct for future development. The total study duration includes follow-up for up to 12 months or longer for some outcome measures.

CONDITIONS

Brief Title

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Research Team

S

Seni S Lu, Phd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here